XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
Subscribe To Our Newsletter & Stay Updated
